| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from issuance of common stock of majority-owned subsidiary | 700,000 | 700,000 |
| Repayment of note payable | 186,223 | - |
| Net cash provided by financing activities | 2,038,777 | 1,542,874 |
| Effect of exchange rates on cash and restricted cash | 414 | 442 |
| Net decrease in cash and restricted cash | -417,247 | -73,255 |
| Cash and cash equivalents at beginning of period | 489,726 | - |
| Cash and cash equivalents at end of period | 72,479 | - |
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)